RTSNRetension Pharmaceuticals
Clinical-stage biopharma developing oral PDE5 inhibitor RTN-001 for hypertension and cardiovascular diseases.
$12IPO price
$46MRaised
$10.53Day-1 close
-12.25%Day-1 return
Clinical-stage biopharma developing oral PDE5 inhibitor RTN-001 for hypertension and cardiovascular diseases.
Company description (source: StockAnalysis)
Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.
51CFO read: Requires CFO with clinical-stage biotech finance: FDA-regulated cap planning, trial cost governance, and IPO-scale fundraising execution.
Management details per the SEC prospectus.
Does your company need this kind of CFO?
51CFO matches you with Western CFOs who have each run a full US IPO — plus other C-level talent. First shortlist within 48 hours; free 30-minute listing-readiness read.
Talk to us